Intangible Assets (Tables)

6 Months Ended

Jun. 30, 2026

Goodwill and Intangible Assets Disclosure [Abstract]

The components of intangible assets were as follows:


	As of June 30, 2026							As of December 31, 2025
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Finite-lived intangible assets:
Customer relationships 1,2	$	4,292	$	(3,136	)	$	1,156	$	4,292	$	(2,985	)	$	1,307
Acquired technology 1		9,200		(5,622	)		3,578		9,200		(5,316	)		3,884
Acquired trademarks 1		570		(570	)		—		570		(570	)		—
	$	14,062	$	(9,328	)	$	4,734	$	14,062	$	(8,871	)	$	5,191

Certain intangible assets were established upon PDL BioPharma, Inc.’s acquisition of LENSAR in May 2017. They are being amortized on a straight-line basis over a period of 15 years. The intangible assets for customer relationships are amortized on a straight-line basis or a double declining basis over their estimated useful lives up to 20 years based on the method that better represents the economic benefits to be obtained.

The Company acquired certain intangible assets for customer relationships from a domestic distributor in an asset acquisition, which are being amortized on a straight-line basis over a period of 10 years.

Schedule of Impairment of Underlying Assets, Remaining Amortization Expense

Based on the intangible assets recorded at June 30, 2026, and assuming no subsequent additions to or impairment of the underlying assets, the remaining amortization expense is expected to be as follows:


Fiscal Year	Amount
Remainder of 2026	$	454
2027		902
2028		694
2029		690
2030		690
2031		690
Thereafter		614
Total remaining estimated amortization expense	$	4,734